epilepsy

Pharma

SK settles with MSN over generic of seizure med Xcopri: reports

SK has struck a settlement with generics manufacturer MSN, which will allow the Korean company to extend its market exclusivity beyond 2032 for Xcopri.

Kevin Dunleavy Aug 19, 2026 11:21am

Filana leaves Cassava roots behind amid branch into epilepsy

Mar 10, 2026 11:05am

Results for UCB's Fintepla pave way for 3rd epileptic indication

Dec 8, 2025 11:19am

SK eyes Xcopri expansion with phase 3 win in new seizure type

Sep 17, 2025 11:32am

UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

Jun 27, 2025 11:28am

Takeda, Enhertu, East Asian American execs—Fierce Pharma Asia

Jan 31, 2025 8:53am